close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.875 -0.265 (-6.40%)
Streaming Delayed Price Updated: 3:42 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend
Editas Medicine (EDIT) stock shows strong technical uptrends and explosive 597% revenue growth, making it a top pick for momentum investors. 
Via Chartmill
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Earnings Scheduled For May 12, 2025
 
Via Benzinga
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Why Editas Medicine Stock Was Skyrocketing This Week
The company's CEO made quite the encouraging statement regarding its immediate future. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Top movers in Wednesday's session
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Wednesday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss
Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for... 
Via Chartmill
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Can This Beaten-Down Stock Bounce Back?
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success. 
Via The Motley Fool
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
Via The Motley Fool
Topics Workforce
2 Beaten-Down Stocks to Avoid
Via The Motley Fool
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
Via The Motley Fool
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
1 Stock Down 97% That Could Double, According to Wall Street
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Editas Medicine: A Cautionary Tale for Investors
Via The Motley Fool
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today